Burden of Vitiligo in Canada: Retrospective Analysis of a Canadian Public Claims Database.

IF 3.1 4区 医学 Q2 DERMATOLOGY
Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-01 Epub Date: 2025-01-22 DOI:10.1177/12034754241304683
Julien Ringuet, Grace K Wong, Véronique Baribeau, Sunil Kalia, Josée Brisebois, Jean Lachaine
{"title":"Burden of Vitiligo in Canada: Retrospective Analysis of a Canadian Public Claims Database.","authors":"Julien Ringuet, Grace K Wong, Véronique Baribeau, Sunil Kalia, Josée Brisebois, Jean Lachaine","doi":"10.1177/12034754241304683","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vitiligo is an autoimmune disease resulting in skin depigmentation. Treatment options are limited.</p><p><strong>Objectives: </strong>To examine disease burden and healthcare resource utilization (HCRU) among patients with vitiligo in Québec, Canada.</p><p><strong>Methods: </strong>In this retrospective study, data were obtained from the Régie de l'Assurance Maladie du Québec (RAMQ) databases for 125,000 random individuals from January 2010 to December 2019. The <i>International Classification of Diseases, Ninth Revision</i> (<i>ICD-9</i>) diagnostic code [709.x (other skin disorders)] with vitiligo-related treatment was used to identify patients with vitiligo. Patient characteristics and treatments, including treatment type, episodes (treatments used without discontinuation), and sequences (treatment episodes ≥30 days), were assessed. Annualized HCRU and costs (2021 adjusted) included all-cause hospitalization, emergency department visits, outpatient visits, and medications among patients with vitiligo (n = 113) and age- and sex-matched non-vitiligo controls (n = 339).</p><p><strong>Results: </strong>Of patients with vitiligo (mean age, 50.0 years; 68.1% female) identified using <i>ICD-9</i> code 709.x with vitiligo-related treatment, 36.3% received ≥4 treatment episodes. Treatment patterns were heterogeneous, with 43 different sequences reported. Annualized mean outpatient visits (16.1 vs 5.5) and all-cause outpatient service costs per patient were significantly higher in the vitiligo versus the control group (CAN$1037 vs CAN$523; <i>P</i> < .01). Total all-cause services costs were higher for patients with vitiligo in the year after versus before diagnosis (CAN$3679 vs CAN$2085; <i>P</i> = .04).</p><p><strong>Conclusions: </strong>Vitiligo is associated with significant burden and HCRU among patients in Québec, Canada, who were identified by <i>ICD-9</i> code 709.x plus vitiligo-related treatment. Measurement of true vitiligo burden remains challenging.</p>","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"234-242"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171071/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Medicine and Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/12034754241304683","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vitiligo is an autoimmune disease resulting in skin depigmentation. Treatment options are limited.

Objectives: To examine disease burden and healthcare resource utilization (HCRU) among patients with vitiligo in Québec, Canada.

Methods: In this retrospective study, data were obtained from the Régie de l'Assurance Maladie du Québec (RAMQ) databases for 125,000 random individuals from January 2010 to December 2019. The International Classification of Diseases, Ninth Revision (ICD-9) diagnostic code [709.x (other skin disorders)] with vitiligo-related treatment was used to identify patients with vitiligo. Patient characteristics and treatments, including treatment type, episodes (treatments used without discontinuation), and sequences (treatment episodes ≥30 days), were assessed. Annualized HCRU and costs (2021 adjusted) included all-cause hospitalization, emergency department visits, outpatient visits, and medications among patients with vitiligo (n = 113) and age- and sex-matched non-vitiligo controls (n = 339).

Results: Of patients with vitiligo (mean age, 50.0 years; 68.1% female) identified using ICD-9 code 709.x with vitiligo-related treatment, 36.3% received ≥4 treatment episodes. Treatment patterns were heterogeneous, with 43 different sequences reported. Annualized mean outpatient visits (16.1 vs 5.5) and all-cause outpatient service costs per patient were significantly higher in the vitiligo versus the control group (CAN$1037 vs CAN$523; P < .01). Total all-cause services costs were higher for patients with vitiligo in the year after versus before diagnosis (CAN$3679 vs CAN$2085; P = .04).

Conclusions: Vitiligo is associated with significant burden and HCRU among patients in Québec, Canada, who were identified by ICD-9 code 709.x plus vitiligo-related treatment. Measurement of true vitiligo burden remains challenging.

加拿大白癜风的负担:加拿大公共索赔数据库的回顾性分析。
背景:白癜风是一种导致皮肤色素沉着的自身免疫性疾病。治疗选择是有限的。目的:了解加拿大曲海省白癜风患者的疾病负担和医疗资源利用情况。方法:在这项回顾性研究中,从2010年1月至2019年12月,随机抽取12.5万名个体的数据,从RAMQ数据库中获取数据。国际疾病分类第九次修订(ICD-9)诊断代码[709]。X(其他皮肤疾病)]与白癜风相关的治疗被用来识别白癜风患者。评估患者特征和治疗,包括治疗类型、发作(不间断使用的治疗)和序列(治疗发作≥30天)。年化HCRU和成本(2021年调整)包括白癜风患者(113例)和年龄和性别匹配的非白癜风对照组(339例)的全因住院、急诊就诊、门诊就诊和药物治疗。结果:白癜风患者(平均年龄50.0岁;68.1%女性),使用ICD-9代码709进行鉴定。X患者接受白癜风相关治疗,36.3%患者接受≥4次治疗。治疗模式是异质性的,报道了43种不同的序列。白癜风患者的年平均门诊次数(16.1次vs 5.5次)和每位患者的全因门诊费用显著高于对照组(1037加元vs 523加元;P < 0.01)。与诊断前相比,白癜风患者在诊断后一年的全因服务总成本更高(3679加元对2085加元;P = .04)。结论:根据ICD-9代码709,在加拿大qu忧郁患者中,白癜风与显著的负担和HCRU相关。X加上白癜风相关的治疗。测量白癜风的真实负担仍然具有挑战性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.30%
发文量
98
审稿时长
6-12 weeks
期刊介绍: Journal of Cutaneous Medicine and Surgery (JCMS) aims to reflect the state of the art in cutaneous biology and dermatology by providing original scientific writings, as well as a complete critical review of the dermatology literature for clinicians, trainees, and academicians. JCMS endeavours to bring readers cutting edge dermatologic information in two distinct formats. Part of each issue features scholarly research and articles on issues of basic and applied science, insightful case reports, comprehensive continuing medical education, and in depth reviews, all of which provide theoretical framework for practitioners to make sound practical decisions. The evolving field of dermatology is highlighted through these articles. In addition, part of each issue is dedicated to making the most important developments in dermatology easily accessible to the clinician by presenting well-chosen, well-written, and highly organized information in a format that is interesting, clearly presented, and useful to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信